Patients Report Recurring Issues with Generic Wellbutrin, FDA Scrutiny Renewed
Numerous patients are reporting a resurgence of adverse effects after switching to generic versions of the antidepressant Wellbutrin XL, prompting renewed calls for greater oversight of generic drug manufacturing.
Reports began surfacing in 2007, with patients experiencing a return of depression symptoms, alongside side effects including panic attacks, headaches, nausea, and anxiety after being switched from brand-name Wellbutrin XL 300 to generic bupropion. The Food and Drug Administration (FDA) acknowledged issues with some generic formulations in 2012, leading to a recall of certain bupropion products. However, recent complaints suggest the problem persists, with some patients finding symptom relief only with the brand-name medication.
The high cost of brand-name Wellbutrin XL presents a significant barrier for many, with prices reaching approximately $3,000 per month even with discount programs like GoodRx. Some patients are exploring alternatives, such as purchasing medication from reputable Canadian online pharmacies, where a three-month supply can cost between $170 and $190, as listed on PharmacyChecker.com. Access to affordable and effective medication is a critical component of mental healthcare, and disruptions in treatment can have serious consequences.
In addition to the Wellbutrin concerns, readers have also inquired about managing travel-related allergies. Experts suggest topical antihistamines like azelastine (Astepro) may help combat nasal allergy symptoms and potentially reduce the risk of catching colds or COVID-19, according to a study published in JAMA Internal Medicine.
The FDA has not yet issued a statement regarding the recent influx of complaints, but officials are expected to review the available data and determine if further action is necessary.
